Last 12 months
Inside the activity.
0 purchase rows · 240 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 200 |
| Dec 2025 | 0 | 3 |
| Jan 2026 | 0 | 31 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 2 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 3 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 01, 2015 Filed Feb 3, 2015 21:08 UTC |
Ricks David ASVP and Pres, Lilly Bio-Meds
|
Exercise / conversionCommon Stock | 12,591 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-15-000066 · wf-form4_142299772208656.xml · nonDerivative · entry 1 Ricks David A · CIK 0001538604 · SVP and Pres, Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,994 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2015 Filed Feb 3, 2015 21:11 UTC |
Simmons Jeffrey NSVP&Pres. Elanco Animal Health
|
Exercise / conversionRestricted Stock Unit · Derivative | 12,591 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-15-000068 · wf-form4_142299786163667.xml · derivative · entry 4 Simmons Jeffrey N · CIK 0001479079 · SVP&Pres. Elanco Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,591 shares Expires 2015-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2015 Filed Feb 3, 2015 21:11 UTC |
Simmons Jeffrey NSVP&Pres. Elanco Animal Health
|
Tax withholdingCommon Stock | 5,824 | $72.00 | $419,328.00 |
DisclosureSEC source: 0000059478-15-000068 · wf-form4_142299786163667.xml · nonDerivative · entry 2 Simmons Jeffrey N · CIK 0001479079 · SVP&Pres. Elanco Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,856 Read SEC document |
| February 01, 2015 Filed Feb 3, 2015 21:11 UTC |
Simmons Jeffrey NSVP&Pres. Elanco Animal Health
|
Exercise / conversionCommon Stock | 12,591 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-15-000068 · wf-form4_142299786163667.xml · nonDerivative · entry 1 Simmons Jeffrey N · CIK 0001479079 · SVP&Pres. Elanco Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,680 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2015 Filed Feb 3, 2015 21:13 UTC |
Walsh Fionnuala MSVP, Global Quality
|
Exercise / conversionRestricted Stock Unit · Derivative | 5,246 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-15-000070 · wf-form4_142299797215088.xml · derivative · entry 6 Walsh Fionnuala M · CIK 0001524637 · SVP, Global Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,246 shares Expires 2015-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2015 Filed Feb 3, 2015 21:13 UTC |
Walsh Fionnuala MSVP, Global Quality
|
Tax withholdingCommon Stock | 2,467 | $72.00 | $177,624.00 |
DisclosureSEC source: 0000059478-15-000070 · wf-form4_142299797215088.xml · nonDerivative · entry 2 Walsh Fionnuala M · CIK 0001524637 · SVP, Global Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,807 Read SEC document |
| February 01, 2015 Filed Feb 3, 2015 21:13 UTC |
Walsh Fionnuala MSVP, Global Quality
|
Exercise / conversionCommon Stock | 5,246 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-15-000070 · wf-form4_142299797215088.xml · nonDerivative · entry 1 Walsh Fionnuala M · CIK 0001524637 · SVP, Global Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,274 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 30, 2015 Filed Jan 30, 2015 22:53 UTC |
Alvarez RalphDirector
|
GrantCommon Stock | 138 | $72.03 | $9,940.14 |
DisclosureSEC source: 0000059478-15-000048 · wf-form4_142265840306123.xml · nonDerivative · entry 1 Alvarez Ralph · CIK 0001310215 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,712 Read SEC document |
| January 28, 2015 Filed Jan 30, 2015 22:10 UTC |
Barnes Melissa SChief Eth/Cmpl Ofcr & SVP, ERM
|
GrantRestricted Stock Unit · Derivative | 2,072 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-15-000018 · wf-form4_142265583186576.xml · derivative · entry 3 Barnes Melissa S · CIK 0001566364 · Chief Eth/Cmpl Ofcr & SVP, ERM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,072 Underlying: Common Stock · 2,072 shares Expires 2016-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 28, 2015 Filed Jan 30, 2015 22:10 UTC |
Barnes Melissa SChief Eth/Cmpl Ofcr & SVP, ERM
|
GrantCommon Stock | 2,943 | $70.97 | $208,864.71 |
DisclosureSEC source: 0000059478-15-000018 · wf-form4_142265583186576.xml · nonDerivative · entry 1 Barnes Melissa S · CIK 0001566364 · Chief Eth/Cmpl Ofcr & SVP, ERM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,587 Read SEC document |
| January 28, 2015 Filed Jan 30, 2015 22:12 UTC |
Conterno Enrique ASr. VP & Pres., Lilly Diabetes
|
GrantRestricted Stock Unit · Derivative | 10,360 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-15-000020 · wf-form4_142265593700407.xml · derivative · entry 3 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,360 Underlying: Common Stock · 10,360 shares Expires 2016-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 28, 2015 Filed Jan 30, 2015 22:12 UTC |
Conterno Enrique ASr. VP & Pres., Lilly Diabetes
|
GrantCommon Stock | 30,037 | $70.97 | $2,131,725.89 |
DisclosureSEC source: 0000059478-15-000020 · wf-form4_142265593700407.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,400 Read SEC document |
| January 28, 2015 Filed Jan 30, 2015 22:16 UTC |
Crowe Maria APresident, Mfg. Operations
|
GrantRestricted Stock Unit · Derivative | 7,252 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-15-000022 · wf-form4_142265615868896.xml · derivative · entry 2 Crowe Maria A · CIK 0001538603 · President, Mfg. Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,252 Underlying: Common Stock · 7,252 shares Expires 2016-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 28, 2015 Filed Jan 30, 2015 22:16 UTC |
Crowe Maria APresident, Mfg. Operations
|
GrantCommon Stock | 20,753 | $70.97 | $1,472,840.41 |
DisclosureSEC source: 0000059478-15-000022 · wf-form4_142265615868896.xml · nonDerivative · entry 1 Crowe Maria A · CIK 0001538603 · President, Mfg. Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,798 Read SEC document |
| January 28, 2015 Filed Jan 30, 2015 22:18 UTC |
Fry Stephen FSVP, HR & Diversity
|
GrantRestricted Stock Unit · Derivative | 7,252 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-15-000024 · wf-form4_142265628957505.xml · derivative · entry 3 Fry Stephen F · CIK 0001513324 · SVP, HR & Diversity 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,252 Underlying: Common Stock · 7,252 shares Expires 2016-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 28, 2015 Filed Jan 30, 2015 22:18 UTC |
Fry Stephen FSVP, HR & Diversity
|
GrantCommon Stock | 18,855 | $70.97 | $1,338,139.35 |
DisclosureSEC source: 0000059478-15-000024 · wf-form4_142265628957505.xml · nonDerivative · entry 1 Fry Stephen F · CIK 0001513324 · SVP, HR & Diversity 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,163 Read SEC document |
| January 28, 2015 Filed Jan 30, 2015 22:21 UTC |
Harrington Michael JSenior VP and General Counsel
|
GrantRestricted Stock Unit · Derivative | 9,066 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-15-000026 · wf-form4_142265646707113.xml · derivative · entry 3 Harrington Michael J · CIK 0001566340 · Senior VP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,066 Underlying: Common Stock · 9,066 shares Expires 2016-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 28, 2015 Filed Jan 30, 2015 22:21 UTC |
Harrington Michael JSenior VP and General Counsel
|
GrantCommon Stock | 7,466 | $70.97 | $529,862.02 |
DisclosureSEC source: 0000059478-15-000026 · wf-form4_142265646707113.xml · nonDerivative · entry 1 Harrington Michael J · CIK 0001566340 · Senior VP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,518 Read SEC document |
| January 28, 2015 Filed Jan 30, 2015 22:22 UTC |
LECHLEITER JOHN CDirector · Chairman, President and CEO
|
GrantRestricted Stock Unit · Derivative | 46,623 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-15-000028 · wf-form4_142265656648353.xml · derivative · entry 6 LECHLEITER JOHN C · CIK 0001209281 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,623 Underlying: Common Stock · 46,623 shares Expires 2016-02-01 F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 28, 2015 Filed Jan 30, 2015 22:22 UTC |
LECHLEITER JOHN CDirector · Chairman, President and CEO
|
GrantCommon Stock | 107,344 | $70.97 | $7,618,203.68 |
DisclosureSEC source: 0000059478-15-000028 · wf-form4_142265656648353.xml · nonDerivative · entry 1 LECHLEITER JOHN C · CIK 0001209281 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 634,622 Read SEC document |
| January 28, 2015 Filed Jan 30, 2015 22:24 UTC |
Lundberg Jan MEVP,Science&Tech and Pres. LRL
|
GrantRestricted Stock Unit · Derivative | 15,541 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-15-000030 · wf-form4_142265665197791.xml · derivative · entry 3 Lundberg Jan M · CIK 0001480120 · EVP,Science&Tech and Pres. LRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,541 Underlying: Common Stock · 15,541 shares Expires 2016-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 28, 2015 Filed Jan 30, 2015 22:24 UTC |
Lundberg Jan MEVP,Science&Tech and Pres. LRL
|
GrantCommon Stock | 44,073 | $70.97 | $3,127,860.81 |
DisclosureSEC source: 0000059478-15-000030 · wf-form4_142265665197791.xml · nonDerivative · entry 1 Lundberg Jan M · CIK 0001480120 · EVP,Science&Tech and Pres. LRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,131 Read SEC document |
| January 28, 2015 Filed Jan 30, 2015 22:36 UTC |
Mahony SusanSVP & Pres., Lilly Oncology
|
GrantRestricted Stock Unit · Derivative | 9,843 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-15-000032 · wf-form4_142265738408482.xml · derivative · entry 5 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,843 Underlying: Common Stock · 9,843 shares Expires 2016-02-01 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 28, 2015 Filed Jan 30, 2015 22:36 UTC |
Mahony SusanSVP & Pres., Lilly Oncology
|
GrantCommon Stock | 1,174 | $70.97 | $83,318.78 |
DisclosureSEC source: 0000059478-15-000032 · wf-form4_142265738408482.xml · nonDerivative · entry 3 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Indirect · by husband Disclosed balance after: 8,984 F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document |
| January 28, 2015 Filed Jan 30, 2015 22:36 UTC |
Mahony SusanSVP & Pres., Lilly Oncology
|
GrantCommon Stock | 27,287 | $70.97 | $1,936,558.39 |
DisclosureSEC source: 0000059478-15-000032 · wf-form4_142265738408482.xml · nonDerivative · entry 1 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,817 Read SEC document |
| January 28, 2015 Filed Jan 30, 2015 22:38 UTC |
Peterson Barton RSr. VP, Corp. Affairs & Comm.
|
GrantRestricted Stock Unit · Derivative | 5,698 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-15-000034 · wf-form4_142265747616084.xml · derivative · entry 3 Peterson Barton R · CIK 0001466550 · Sr. VP, Corp. Affairs & Comm. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,698 Underlying: Common Stock · 5,698 shares Expires 2016-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 28, 2015 Filed Jan 30, 2015 22:38 UTC |
Peterson Barton RSr. VP, Corp. Affairs & Comm.
|
GrantCommon Stock | 16,051 | $70.97 | $1,139,139.47 |
DisclosureSEC source: 0000059478-15-000034 · wf-form4_142265747616084.xml · nonDerivative · entry 1 Peterson Barton R · CIK 0001466550 · Sr. VP, Corp. Affairs & Comm. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,700 Read SEC document |
| January 28, 2015 Filed Jan 30, 2015 22:40 UTC |
Rice Derica WEVP-Global Services and CFO
|
GrantRestricted Stock Unit · Derivative | 19,685 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-15-000036 · wf-form4_142265764075089.xml · derivative · entry 5 Rice Derica W · CIK 0001359067 · EVP-Global Services and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,685 Underlying: Common Stock · 19,685 shares Expires 2016-02-01 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 28, 2015 Filed Jan 30, 2015 22:40 UTC |
Rice Derica WEVP-Global Services and CFO
|
GrantCommon Stock | 56,158 | $70.97 | $3,985,533.26 |
DisclosureSEC source: 0000059478-15-000036 · wf-form4_142265764075089.xml · nonDerivative · entry 1 Rice Derica W · CIK 0001359067 · EVP-Global Services and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,158 Read SEC document |
| January 28, 2015 Filed Jan 30, 2015 22:42 UTC |
Ricks David ASVP and Pres, Lilly Bio-Meds
|
GrantRestricted Stock Unit · Derivative | 9,843 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-15-000038 · wf-form4_142265776706356.xml · derivative · entry 3 Ricks David A · CIK 0001538604 · SVP and Pres, Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,843 Underlying: Common Stock · 9,843 shares Expires 2016-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 28, 2015 Filed Jan 30, 2015 22:42 UTC |
Ricks David ASVP and Pres, Lilly Bio-Meds
|
GrantCommon Stock | 27,248 | $70.97 | $1,933,790.56 |
DisclosureSEC source: 0000059478-15-000038 · wf-form4_142265776706356.xml · nonDerivative · entry 1 Ricks David A · CIK 0001538604 · SVP and Pres, Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,403 Read SEC document |
| January 28, 2015 Filed Jan 30, 2015 22:45 UTC |
Simmons Jeffrey NSVP&Pres. Elanco Animal Health
|
GrantRestricted Stock Unit · Derivative | 9,843 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-15-000040 · wf-form4_142265788981247.xml · derivative · entry 3 Simmons Jeffrey N · CIK 0001479079 · SVP&Pres. Elanco Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,843 Underlying: Common Stock · 9,843 shares Expires 2016-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 28, 2015 Filed Jan 30, 2015 22:45 UTC |
Simmons Jeffrey NSVP&Pres. Elanco Animal Health
|
GrantCommon Stock | 27,653 | $70.97 | $1,962,533.41 |
DisclosureSEC source: 0000059478-15-000040 · wf-form4_142265788981247.xml · nonDerivative · entry 1 Simmons Jeffrey N · CIK 0001479079 · SVP&Pres. Elanco Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,089 Read SEC document |
| January 28, 2015 Filed Jan 30, 2015 22:47 UTC |
Walsh Fionnuala MSVP, Global Quality
|
GrantRestricted Stock Unit · Derivative | 4,144 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-15-000042 · wf-form4_142265802870956.xml · derivative · entry 5 Walsh Fionnuala M · CIK 0001524637 · SVP, Global Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,144 Underlying: Common Stock · 4,144 shares Expires 2016-02-01 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 28, 2015 Filed Jan 30, 2015 22:47 UTC |
Walsh Fionnuala MSVP, Global Quality
|
GrantCommon Stock | 8,369 | $70.97 | $593,947.93 |
DisclosureSEC source: 0000059478-15-000042 · wf-form4_142265802870956.xml · nonDerivative · entry 2 Walsh Fionnuala M · CIK 0001524637 · SVP, Global Quality 10b5-1 filing: Not disclosed Ownership: Indirect · by husband Disclosed balance after: 22,578 F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document |
| January 28, 2015 Filed Jan 30, 2015 22:47 UTC |
Walsh Fionnuala MSVP, Global Quality
|
GrantCommon Stock | 12,535 | $70.97 | $889,608.95 |
DisclosureSEC source: 0000059478-15-000042 · wf-form4_142265802870956.xml · nonDerivative · entry 1 Walsh Fionnuala M · CIK 0001524637 · SVP, Global Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,028 Read SEC document |
| January 28, 2015 Filed Jan 30, 2015 22:48 UTC |
Zakrowski Donald AChief Accounting Officer
|
GrantCommon Stock | 1,373 | $70.97 | $97,441.81 |
DisclosureSEC source: 0000059478-15-000044 · wf-form4_142265812511214.xml · nonDerivative · entry 1 Zakrowski Donald A · CIK 0001561539 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,420 Read SEC document |
| January 28, 2015 Filed Jan 30, 2015 22:50 UTC |
Zulueta Alfonso GSVP& Pres., Emerging Markets
|
GrantCommon Stock | 11,532 | $70.97 | $818,426.04 |
DisclosureSEC source: 0000059478-15-000046 · wf-form4_142265822009833.xml · nonDerivative · entry 1 Zulueta Alfonso G · CIK 0001596336 · SVP& Pres., Emerging Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,692 Read SEC document |
| December 31, 2014 Filed Jan 5, 2015 16:48 UTC |
Alvarez RalphDirector
|
GrantCommon Stock | 123 | $69.67 | $8,569.41 |
DisclosureSEC source: 0000059478-15-000002 · wf-form4_142047650094432.xml · nonDerivative · entry 1 Alvarez Ralph · CIK 0001310215 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,574 Read SEC document |
| December 10, 2014 Filed Dec 12, 2014 22:06 UTC |
Conterno Enrique ASr. VP & Pres., Lilly Diabetes
|
Exercise / conversionEmployee stock option 2/05 (right to buy) · Derivative | 7,101 | $0.00 Strike: $55.65 | $0.00 |
DisclosureSEC source: 0000059478-14-000222 · wf-form4_141842196908039.xml · derivative · entry 4 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,101 shares Expires 2015-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 10, 2014 Filed Dec 12, 2014 22:06 UTC |
Conterno Enrique ASr. VP & Pres., Lilly Diabetes
|
Tax withholdingCommon Stock | 6,046 | $72.21 | $436,581.66 |
DisclosureSEC source: 0000059478-14-000222 · wf-form4_141842196908039.xml · nonDerivative · entry 2 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,791 Read SEC document |
| December 10, 2014 Filed Dec 12, 2014 22:06 UTC |
Conterno Enrique ASr. VP & Pres., Lilly Diabetes
|
Exercise / conversionCommon Stock | 7,101 | $55.65 | $395,170.65 |
DisclosureSEC source: 0000059478-14-000222 · wf-form4_141842196908039.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,837 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 10, 2014 Filed Dec 16, 2014 21:04 UTC Amendment |
Conterno Enrique ASr. VP & Pres., Lilly Diabetes
|
Tax withholdingCommon Stock | 5,474 | $72.21 | $395,277.54 |
DisclosureSEC source: 0000059478-14-000226 · wf-form4a_141876386481023.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,363 F1 · shares: This amendment is being filed to correctly report the amount disposed in column 4, and to correct the number of securities beneficially owned following the reported transaction, as reported in column 5. F1 · balance_after: This amendment is being filed to correctly report the amount disposed in column 4, and to correct the number of securities beneficially owned following the reported transaction, as reported in column 5. Read SEC document |
| December 04, 2014 Filed Dec 5, 2014 19:23 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 190,000 | $71.92 | $13,664,800.00 |
DisclosureSEC source: 0001209191-14-073334 · doc4.xml · nonDerivative · entry 1 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,405,804 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.445 to $72.40, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| December 04, 2014 Filed Jan 29, 2015 18:26 UTC |
LECHLEITER JOHN CDirector · Chairman, President and CEO
|
GiftCommon Stock | 393 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-15-000009 · wf-form5_142255599923302.xml · nonDerivative · entry 4 LECHLEITER JOHN C · CIK 0001209281 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 527,278 Read SEC document |
| December 04, 2014 Filed Feb 4, 2015 18:58 UTC |
Mahony SusanSVP & Pres., Lilly Oncology
|
GiftCommon Stock | 730 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-15-000072 · wf-form5_142307632673641.xml · nonDerivative · entry 1 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,757 Read SEC document |
| December 03, 2014 Filed Jan 29, 2015 18:26 UTC |
LECHLEITER JOHN CDirector · Chairman, President and CEO
|
GiftCommon Stock | 1,179 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-15-000009 · wf-form5_142255599923302.xml · nonDerivative · entry 3 LECHLEITER JOHN C · CIK 0001209281 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 527,671 Read SEC document |
| December 02, 2014 Filed Dec 3, 2014 16:47 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 38,765 | $70.52 | $2,733,707.80 |
DisclosureSEC source: 0001209191-14-072576 · doc4.xml · nonDerivative · entry 2 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,595,804 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.39 to $70.76, inclusive. Read SEC document |
| December 02, 2014 Filed Dec 3, 2014 16:47 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 141,235 | $70.03 | $9,890,687.05 |
DisclosureSEC source: 0001209191-14-072576 · doc4.xml · nonDerivative · entry 1 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,634,569 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.39 to $70.38, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. Read SEC document |
| November 28, 2014 Filed Dec 2, 2014 20:31 UTC |
Alvarez RalphDirector
|
GrantCommon Stock | 2,282 | $67.29 | $153,555.78 |
DisclosureSEC source: 0000059478-14-000194 · wf-form4_141755227227083.xml · nonDerivative · entry 1 Alvarez Ralph · CIK 0001310215 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,282 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.